Jump to content

Carlos Cruchaga

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:Carlos Cruchaga)
Carlos Cruchaga
NationalitySpanish
Alma mater
Known forIdentification and characterization of TREM2
Scientific career
FieldsNeurogenomics
Institutions
Doctoral advisorJuan Jose Martinez Irujo
WebsiteLab website

Carlos Cruchaga is a human genomicist with expertise in multi-omics, informatics, and neurodegeneration, with a focus on Alzheimer's and Parkinson's Disease. He is a Professor of Psychiatry, Neurology and Genetics and Washington University School of Medicine. He is founding director of the Neurogenomics and Informatic (NGI) center at Washington University School of Medicine.[1]

His lab uses deep molecular profiling of human samples relevant to brain and neurodegenerative diseases. He is best known for using endophenotypes and biomarkers as quantitative traits for genetics studies, which led to the identification of novel variants associated with Alzheimer's Disease risk, onset and progression.

Education and early career

[edit]

After receiving his undergraduate degree Biochemistry in and his graduate training in Biochemistry and Molecular Biology in 2005 at University of Navarra (Spain).[2] Cruchaga studied the genetic basis of Alzheimer's and Parkinson disease under Professors Pau Pastor. He then, completed his postdoctoral training in neurogenomics and system biology on Alison Goate lab. Cruchaga started his own lab at Washington University School of Medicine[3] in 2011. [4]

Research

[edit]

Cruchaga and his lab generates and analyze human multi-omic (genetic, epigenomic, transcriptomic, proteomic, metabolomic and lipidomic) data generated from well clinically-characterized cohorts in order to identify novel genes and pathways implicated on neurodegenerative disease, mainly Alzheimer's and Parkinson's disease, to identify novel molecular biomarkers and druggable targets.

Some of Dr. Cruchaga seminal contributions to the neurodegeneration field include the identification of MS4A4A as the major regulator of TREM2[5] and the identification of multiple TREM2 Alzheimer Disease risk variants.[6][7] His lab also analyzed for the first time the role of Circular RNA in Alzheimer disease pathology.[8] He and his team identified 148 circRNA that show significant and consistent association with Alzheimer Disease risk pathological traits and additional analyses suggest that circRNA could be informative biomarkers for Alzheimer disease. Dr. Cruchaga also developed a digital deconvolution algorithm to determine the cell proportions from brain RNA-seq data that lead to the identification of TMEM106B as a protective gene for neurodegeneration.[9]

Title and Affiliations

[edit]

Dr. Cruchaga is the current Director of the Neurogenomics and Informatic Center, and the Hope Center DNA and RNA Purification Core.[10] He is also the leader of the Knight-ADRC Genetics Core,[11] the DIAN Genetics Core,[12] the Dystonia Coalition Biobank,[13] and co-leader of the Alzheimer's Biomarkers Consortium — Down Syndrome (ABC-DS) Genetics Core.[14] He is also a scientific advisor of the McDonnell Genome Institute (MGI) at Washington University.[15]

Awards and Honnors

[edit]

Cruchaga' work has been funded by American Federation for Aging Research, National Institutes of Health, the Bright Focus Foundation, and Michael J Fox Foundation. In 2022, he was awarded the Alzheimer's Association prestigious Zenith Award[permanent dead link‍].[16]

  • 2019 Named Barbara Burton and Reuben M. Morriss III Professor in Psychiatry.[17]
  • 2022 Alzheimer's Association Zenith Award

Grants

[edit]

Partial list[18]

Project Title Role in Project Founding Source & Type
Genetic Modifiers of Cerebrospinal Fluid TREM2 in Alzheimer's Disease.[19] Principal Investigator NIA-R01
Identification of Genetic Variants Associated with Rate of Disease Progression.[20] Principal Investigator NIA-P01
Using Quantitative Traits to Identify Novel Genes for Alzheimers Disease and Other Complex Traits.[21] Principal Investigator NIA-RF1
The Familial Alzheimer Sequencing (Fase) Project.[22] Principal Investigator NIA-U01
Molecular Mechanism of the Central Regulator of TREM2 Dysfunction.[23] Co-Principal Investigator Chan Zuckerberg Science Initiative (CZI) Neurodegeneration Challenge Network

Publications

[edit]

Semantic Scholar lists 210 publications, 20,350 citations and 627 influential citations of Cruchaga's peer-reviewed and original contribution as of 2020.[24][25]

  • Cruchaga C, et al. (2013. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 2013; 78(2):256-68.[26]
  • Cruchaga C et al (2014). Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature; 505(7484):550-4.[27]
  • Li Z, et al. (2019) The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropath 2019 Aug 27. doi: 10.1007/s00401-019-02066-0.[28]
  • Deming Y, et al. (2019) The MS4A gene cluster is a key regulator of soluble TREM2 and Alzheimer disease risk. Sci Transl Med. 2019 Aug 14;11(505). pii: eaau2291. doi: 10.1126/scitranslmed.aau2291.[29]
  • Dube U, et al (2019). An atlas of cortical circular RNA expression demonstrates clinical and pathological associations with Alzheimer disease. Nature Neuroscience.[30]

References

[edit]
  1. ^ "NeuroGenomics and Informatics Center". NGI. 11 October 2018.
  2. ^ "University of Navarra". University of Navarra.
  3. ^ "Washington University". School of Medicine.
  4. ^ https://cruchagalab.wustl.edu/
  5. ^ Deming, Yuetiva; et al. (2019). "The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk". Science Translational Medicine. 11 (505). doi:10.1126/scitranslmed.aau2291. PMC 6697053. PMID 31413141.
  6. ^ Guerreiro, R; Wojtas, A; Bras, J; Carrasquillo, M; Rogaeva, E; Majounie, E; Cruchaga, C; Sassi, C; Kauwe, JS; Younkin, S; Hazrati, L; Collinge, J; Pocock, J; Lashley, T; Williams, J; Lambert, JC; Amouyel, P; Goate, A; Rademakers, R; Morgan, K; Powell, J; St George-Hyslop, P; Singleton, A; Hardy, J; Alzheimer Genetic Analysis, Group. (10 January 2013). "TREM2 variants in Alzheimer's disease". The New England Journal of Medicine. 368 (2): 117–27. doi:10.1056/NEJMoa1211851. PMC 3631573. PMID 23150934.
  7. ^ Jin, SC; Benitez, BA; Karch, CM; Cooper, B; Skorupa, T; Carrell, D; Norton, JB; Hsu, S; Harari, O; Cai, Y; Bertelsen, S; Goate, AM; Cruchaga, C (1 November 2014). "Coding variants in TREM2 increase risk for Alzheimer's disease". Human Molecular Genetics. 23 (21): 5838–46. doi:10.1093/hmg/ddu277. PMC 4189899. PMID 24899047.
  8. ^ Dube, U; Del-Aguila, JL; Li, Z; Budde, JP; Jiang, S; Hsu, S; Ibanez, L; Fernandez, MV; Farias, F; Norton, J; Gentsch, J; Wang, F; Dominantly Inherited Alzheimer Network, (DIAN).; Salloway, S; Masters, CL; Lee, JH; Graff-Radford, NR; Chhatwal, JP; Bateman, RJ; Morris, JC; Karch, CM; Harari, O; Cruchaga, C (November 2019). "An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations". Nature Neuroscience. 22 (11): 1903–1912. doi:10.1038/s41593-019-0501-5. PMC 6858549. PMID 31591557.
  9. ^ Li, Z; Farias, FHG; Dube, U; Del-Aguila, JL; Mihindukulasuriya, KA; Fernandez, MV; Ibanez, L; Budde, JP; Wang, F; Lake, AM; Deming, Y; Perez, J; Yang, C; Bahena, JA; Qin, W; Bradley, JL; Davenport, R; Bergmann, K; Morris, JC; Perrin, RJ; Benitez, BA; Dougherty, JD; Harari, O; Cruchaga, C (January 2020). "The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion". Acta Neuropathologica. 139 (1): 45–61. doi:10.1007/s00401-019-02066-0. PMC 6942643. PMID 31456032. S2CID 201661399.
  10. ^ "Hope Center DNA and RNA Purification Core". 29 August 2012.
  11. ^ Knight-ADRC. "Charles F. And Joanne Knight ADRC at Washington University".
  12. ^ "DIAN Study".
  13. ^ "Dystonia Coalition".
  14. ^ "ABC-DS".
  15. ^ "MGI".
  16. ^ "Cruchaga awarded Zenith Fellowship Award". 6 October 2022.
  17. ^ "Cruchaga named Morriss Professor". 22 July 2022.
  18. ^ "Carlos Cruchaga, PhD - US grants. Neurotree". Retrieved 30 April 2020.
  19. ^ "Genetic Modifiers of Cerebrospinal Fluid TREM2 in Alzheimer's Disease".
  20. ^ "Identification of Genetic Variants Associated with Rate of Disease Progression".
  21. ^ "Using Quantitative Traits to Identify Novel Genes for Alzheimers Disease and Other Complex Traits".
  22. ^ "The Familial Alzheimer Sequencing (Fase) Project".
  23. ^ "Molecular Mechanism of the Central Regulator of TREM2 Dysfunction". Archived from the original on 2019-12-31. Retrieved 2020-04-30.
  24. ^ "Carlos Cruchaga - Semantic Scholar".
  25. ^ "Carlos Cruchaga - Google Scholar".
  26. ^ Cruchaga, C; Kauwe, JS; Harari, O; Jin, SC; Cai, Y; Karch, CM; Benitez, BA; Jeng, AT; Skorupa, T; Carrell, D; Bertelsen, S; Bailey, M; McKean, D; Shulman, JM; De Jager, PL; Chibnik, L; Bennett, DA; Arnold, SE; Harold, D; Sims, R; Gerrish, A; Williams, J; Van Deerlin, VM; Lee, VM; Shaw, LM; Trojanowski, JQ; Haines, JL; Mayeux, R; Pericak-Vance, MA; Farrer, LA; Schellenberg, GD; Peskind, ER; Galasko, D; Fagan, AM; Holtzman, DM; Morris, JC; GERAD, Consortium.; Alzheimer’s Disease Neuroimaging Initiative, (ADNI).; Alzheimer Disease Genetic Consortium, (ADGC).; Goate, AM (24 April 2013). "GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease". Neuron. 78 (2): 256–68. doi:10.1016/j.neuron.2013.02.026. PMC 3664945. PMID 23562540. S2CID 4461362.
  27. ^ Cruchaga, C; Karch, CM; Jin, SC; Benitez, BA; Cai, Y; Guerreiro, R; Harari, O; Norton, J; Budde, J; Bertelsen, S; Jeng, AT; Cooper, B; Skorupa, T; Carrell, D; Levitch, D; Hsu, S; Choi, J; Ryten, M; Sassi, C; Bras, J; Gibbs, RJ; Hernandez, DG; Lupton, MK; Powell, J; Forabosco, P; Ridge, PG; Corcoran, CD; Tschanz, JT; Norton, MC; Munger, RG; Schmutz, C; Leary, M; Demirci, FY; Bamne, MN; Wang, X; Lopez, OL; Ganguli, M; Medway, C; Turton, J; Lord, J; Braae, A; Barber, I; Brown, K; Alzheimer's Research UK (ARUK), Consortium.; Pastor, P; Lorenzo-Betancor, O; Brkanac, Z; Scott, E; Topol, E; Morgan, K; Rogaeva, E; Singleton, A; Hardy, J; Kamboh, MI; George-Hyslop, PS; Cairns, N; Morris, JC; Kauwe, JSK; Goate, AM (23 January 2014). "Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease". Nature. 505 (7484): 550–554. Bibcode:2014Natur.505..550.. doi:10.1038/nature12825. PMC 4050701. PMID 24336208.
  28. ^ Li, Z; Farias, FHG; Dube, U; Del-Aguila, JL; Mihindukulasuriya, KA; Fernandez, MV; Ibanez, L; Budde, JP; Wang, F; Lake, AM; Deming, Y; Perez, J; Yang, C; Bahena, JA; Qin, W; Bradley, JL; Davenport, R; Bergmann, K; Morris, JC; Perrin, RJ; Benitez, BA; Dougherty, JD; Harari, O; Cruchaga, C (January 2020). "The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion". Acta Neuropathologica. 139 (1): 45–61. doi:10.1007/s00401-019-02066-0. PMC 6942643. PMID 31456032. S2CID 201661399.
  29. ^ Deming, Y; Filipello, F; Cignarella, F; Cantoni, C; Hsu, S; Mikesell, R; Li, Z; Del-Aguila, JL; Dube, U; Farias, FG; Bradley, J; Budde, J; Ibanez, L; Fernandez, MV; Blennow, K; Zetterberg, H; Heslegrave, A; Johansson, PM; Svensson, J; Nellgård, B; Lleo, A; Alcolea, D; Clarimon, J; Rami, L; Molinuevo, JL; Suárez-Calvet, M; Morenas-Rodríguez, E; Kleinberger, G; Ewers, M; Harari, O; Haass, C; Brett, TJ; Benitez, BA; Karch, CM; Piccio, L; Cruchaga, C (14 August 2019). "The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk". Science Translational Medicine. 11 (505): eaau2291. doi:10.1126/scitranslmed.aau2291. PMC 6697053. PMID 31413141. S2CID 199663086.
  30. ^ Dube, U; Del-Aguila, JL; Li, Z; Budde, JP; Jiang, S; Hsu, S; Ibanez, L; Fernandez, MV; Farias, F; Norton, J; Gentsch, J; Wang, F; Dominantly Inherited Alzheimer Network, (DIAN).; Salloway, S; Masters, CL; Lee, JH; Graff-Radford, NR; Chhatwal, JP; Bateman, RJ; Morris, JC; Karch, CM; Harari, O; Cruchaga, C (November 2019). "An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations". Nature Neuroscience. 22 (11): 1903–1912. doi:10.1038/s41593-019-0501-5. PMC 6858549. PMID 31591557.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Carlos_Cruchaga&oldid=1185377921"